Phase 4 N=1,500 CARE FOR ALL：an Evaluation of an Asthma QIP
Asthma
Primary: Change From Baseline in the Proportion of Patients With an ICS-based Maintenance and/or Reliever Treatment — 571; 723 Participants — p=<.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=29 Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
Bipolar Disorder · Schizophrenia · Agitation,Psychomotor
Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — -10.4; -10.0; -10.1; -9.8 score on a scale
Phase 4 N=124 Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Moderate-to-Severe Atopic Dermatitis · Atopic Eczema
Primary: Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) — 76.0 percentage of participants
Phase 4 N=10 Influence of Anesthetic Technique on Acute and Chronic Neuropathic Pain
Acute Pain · Chronic Pain · Hernia
Primary: Pain Score, Chronic — 1.7; 1.5; 0; .8 score on a scale
Phase 4 N=20 Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation
Multiple Sclerosis
Primary: 11C-PBR28 Uptake as Measured by Standardized Uptake Values Normalized by a Pseudoreference Region (SUVR) — 0.9; 0.9; 1.31; 0.84 SUVR — p=0.011
Phase 4 N=20 PFAS Exposure and Immune Response to Vaccination in Adults
Innate Inflammatory Response · Vaccination · Diphtheria
Primary: Change in Tetanus-diphtheria Specific IgG by PFNA Exposure Category — 3.54; 3.39; 2.44; 2.43 log2(fold change) — p=.85
Phase 4 N=92 Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
Type 2 Diabetes Mellitus · Hypogonadism
Primary: Finite Element Analysis of Bone to Measure Bone Strength — 1.2; 1.6; 1.6; 0.88 % change — p=<0.05
Phase 4 N=81 Study of Ketorolac Versus Opioid for Pain After Endoscopy
Kidney Calculi · Ureteral Calculi
Primary: Visual Analog Pain Score — 4.6; 4.5 units on a scale
Phase 4 N=90 PrEP at a Syringe Services Program
Hiv · Substance Use Disorders
Primary: Intracellular Level of Tenofovir Diphosphate Levels Via Dried Blood Spot at 6-month Follow-up — NA fmol/punch
Phase 4 N=124 Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach
Suicidal Ideation
Primary: Perimenstrual Change in Daily Adult Suicidal Ideation Questionnaire (ASIQ) Scores — .178; -.051 Mean Score Change — p=<.001
Phase 4 N=233 Envarsus XR Compared to Immediate Release Tacrolimus
Kidney Transplant Recipients
Primary: Mean Change in Calcineurin Inhibitor-related Symptoms Severity Score — -2.977; -3.139 score on a scale — p=0.944
Phase 4 N=3,626 Norepinephrine vs Phenylephrine During General Anesthesia
Anesthesia · Surgery · Hypotension
Primary: Number of Participants With Assigned Vasopressor Given — 1570; 1627 Participants
Phase 4 N=33 Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants
Intermittent Claudicants
Primary: Maximum Walking Distance (MWD). — 137; 143 Metres
Phase 4 N=71 Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
Asses Immunosuppression Modulation on Renal Recovery Post LT
Primary: Participants Who Have Recovered Renal Function — 28; 20; 11 Participants
Phase 4 N=66 Exploring the Effects of Corticosteroids on the Human Hippocampus
Hydrocortisone · Depression · Healthy Volunteers
Primary: Hippocampal Subfield Activation (Left Hemisphere) — -0.35; 0.03; -0.08; -0.07 Z-Score